Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic: Insulin glargine & fda max : TID per eye or Titrated to glucose; no fixed ceiling

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
Lantus, Basaglar, Semglee, Toujeo (U-300) (1)
classes:
[[:Category:Basal_insulins|Basal insulin]] (1) · [[:Category:Insulins|Insulin]] (1) · [[:Category:Long-acting_insulins|Long-acting insulin analog]] (1)
mechanism:
'"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1)
starting dose:
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (1)
preparations:
100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1)
fda max: (Click arrow to add another value)
routes:
Subcutaneous (never IV; not for use in insulin pumps) (1)
onset:
1-2 hours (1)
duration:
~24 hours per dose (peakless profile by design) (1)
halflife:
~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1)
bioavailability:
~100% from subcutaneous depot (by definition of the route) (1)
pregnancy:
Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
[[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"